AI assistant
Sending…
GlaxoSmithKline PLC — Director's Dealing 2018
Jan 2, 2018
5262_dirs_2018-01-02_b524cf69-25ba-48b7-a06a-34c17b6a2832.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7425A
GlaxoSmithKline PLC
02 January 2018
GlaxoSmithKline plc (the "Company")
Director Shareholding
Further to the announcement made by the Company on 8 November 2017, in respect of the appointment of Dr Hal Barron as Chief Scientific Officer and President, R&D, and Executive Director, Dr Barron assumed his new role on 1 January 2018.
As at the date of his appointment to the Board, Dr Barron held 1,644 American Depositary Shares in the Company.
V A Whyte
Company Secretary
2 January 2018
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBTMJTMBAMBPP
More from GlaxoSmithKline PLC
Report Publication Announcement
2026
May 22
Foreign Filer Report
2026
May 22
Director's Dealing
2026
May 20
Foreign Filer Report
2026
May 20
Foreign Filer Report
2026
May 20
Director's Dealing
2026
May 19
Foreign Filer Report
2026
May 19
Transaction in Own Shares
2026
May 18
Foreign Filer Report
2026
May 18
Foreign Filer Report
2026
May 18